WASHINGTON, July 28 -- Food and Drug Administration has issued a notice called: Fee Rate for Using a Priority Review Voucher in Fiscal Year 2026; Correction.
The notice was published in the Federal Register on July 28 by Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs.
Summary: The Food and Drug Administration (FDA) is amending a notice entitled "Fee Rate for Using a Priority Review Voucher in Fiscal Year 2026" that appeared in the Federal Registeron September 18, 2025. The notice established the FY 2026 priority review fee rate applicable to submission of eligible applications for review of human drug or biological products using a rare pediatric disease, material threat medical countermeasure, or ...